Plasmodium falciparum malaria

Researchers are testing whether a combination of cipargamin and KLU156 (ganaplacide plus lumefantrine) can cure uncomplicated Plasmodium falciparum malaria in children aged 2 to under 12. The trial compares this oral regimen with standard Coartem treatment. The main goal is to se…

This study tests a new triple-drug combination (artemether-lumefantrine-amodiaquine) against standard two-drug treatments for uncomplicated malaria. About 1680 people with malaria will receive one of the treatments and be monitored for 42 days. The goal is to see if the triple th…

This study aims to develop a vaccine to prevent malaria during pregnancy. Researchers will test potential vaccines in the lab using blood samples from pregnant women aged 15-25 in Mali. The goal is to see if these vaccines can block the malaria parasite from attaching to the plac…

This phase 2 trial tests a new malaria vaccine (PfSPZ-LARC2) designed to stop the malaria parasite in the liver before it can cause illness. The study involves 300 healthy women of childbearing age in Mali who plan to become pregnant. Participants receive three doses of the vacci…

This early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects a…

This study tests a new malaria vaccine in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that stop growing in the liver, so they cannot cause blood-stage infection. Participants receive either one or two doses of the vaccine or a placeb…

This study tests the R21/Matrix-M malaria vaccine in about 964 African infants to find the best timing for shots. Researchers compare a compressed schedule (6, 10, 14 weeks) with relaxed schedules (2, 4, 6 months or 3, 6, 9 months) to see which works best with other routine vacci…

This study tests a new malaria vaccine designed to target the parasite at different stages of its life cycle. Researchers will give the vaccine to 56 healthy adults (18-35 years) and children (5-17 months) in Burkina Faso to check its safety and how well it triggers an immune res…

This study is testing whether giving the RTS,S/AS01E malaria vaccine (Mosquirix) in lower doses or on different schedules is safe and triggers a strong immune response in healthy children aged 5 months to 5 years. The goal is to find simpler ways to vaccinate children in areas wh…

This study tests a new way to find and treat a type of malaria (P. vivax) that can hide in the liver and come back months later. Researchers will use a simple blood test to find people who have been infected recently, then give them a treatment to clear the hidden parasites. The …

This study at the National Institutes of Health evaluates and treats people aged 3 and older with known or suspected parasitic infections, such as malaria, intestinal worms, and others. Participants receive standard medical care, not experimental treatments. The goal is to monito…

This study tests whether giving a whole blood transfusion can help children under 5 with severe malaria and very low platelet counts survive. The trial is enrolling 132 children in Zambia. Researchers will compare death rates and blood changes between those who get a transfusion …

This trial evaluates the safety of a single intravenous dose of DON, an experimental drug, in healthy adults, adults with uncomplicated malaria, and children aged 12 months to 14 years with cerebral malaria. Researchers will monitor side effects and measure how the drug moves thr…

This study tests whether adding imatinib, a drug currently used for cancer, to the standard malaria treatment (artemether + lumefantrine) can clear the malaria parasite faster and fight drug resistance. About 1,100 adults with mild to moderate malaria will receive either the stan…

This study will give a combination of two malaria drugs (dihydroartemisinin-piperaquine and primaquine) to entire communities in Ghana every two months for two years. The goal is to see if this approach can reduce the number of people carrying malaria parasites, even those with n…

This study tests newer antimalarial drugs to see if they work as well as the current standard treatment for malaria in early pregnancy. It involves 1,510 pregnant women in Africa. The goal is to find treatments that are both effective and safe for the mother and baby.

This study is checking how effective the R21/Matrix-M malaria vaccine is at protecting children under 5 in Burkina Faso and Uganda, where malaria is common. Researchers will compare vaccination history in children who test positive for malaria against those who test negative. The…

This early-stage trial tests whether two new long-acting injectable drugs, MMV055 and MMV371, are safe and how they work in the body. Up to 72 healthy adults will receive one or two shots and be monitored for up to 48 weeks. The goal is to find a dose that could one day prevent m…

This study is testing whether giving entire communities antimalarial drugs along with a malaria vaccine can reduce the spread of the disease better than drugs alone, vaccine alone, or no extra intervention. About 10,000 people aged 6 months and older in malaria-prone villages wil…

This study in Odisha, India, aims to understand why malaria transmission persists in some areas despite control efforts. Researchers will follow about 3,000 residents to measure hidden infections that don't cause symptoms and may be missed by standard tests. They will also look f…

This early-stage study will check if a new experimental drug for malaria, called GSK3772701, changes how the body processes other medications. Twenty healthy adults aged 18 to 55 will take both GSK3772701 and a common probe drug called midazolam. The goal is to see if GSK3772701 …